TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07638800: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Doses Study of GenSci155 Injection Administered Intravenously in Healthy Adult Trial Participants

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 68 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07638800 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07638800 Rescue Dossier →